MacroGenics (MGNX) vs OnKure Therapeutics (OKUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
MacroGenics (MGNX) has outperformed OnKure Therapeutics (OKUR) over the past year, gaining 40.0% versus a gain of 4.7%. Over five years, MGNX leads with a -89.6% price change compared with -96.2% for OKUR. MacroGenics is the larger company by market cap ($125.3 million vs $111.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MGNX | OKUR |
|---|---|---|
| Share price | $1.96 | $2.70 |
| Market cap | $125.26M | $111.21M |
| 1-day change | -1.01% | -2.17% |
| YTD return | +21.74% | -6.90% |
| 1-year return | +40.00% | +4.65% |
| 5-year return | -89.56% | -96.16% |
| EPS (TTM) | $-2.30 | $-2.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $149.50M | — |
| Revenue growth (YoY) | -0.31% | — |
| Net income (latest FY) | $-74.62M | $-59.52M |
| Gross margin | 100.00% | — |
| Operating margin | -48.72% | — |
| Net margin | -49.91% | — |
| 52-week high | $5.08 | $5.38 |
| 52-week low | $1.32 | $2.01 |
| Distance from 52-week high | -61.42% | -49.81% |
| Analyst consensus | buy | none |
| Avg. price target upside | +308.16% | +464.81% |
| Average volume | 747.02K | 335.78K |
| Shares outstanding | 63.91M | 40.50M |
| Employees | 293 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGNX has outperformed OKUR by 35.3 percentage points over the past year.
About MacroGenics
MGNX stock →MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
About OnKure Therapeutics
OKUR stock →OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 45 employees
MGNX vs OKUR FAQ
Which is bigger, MacroGenics or OnKure Therapeutics?
MacroGenics (MGNX) is larger, with a market capitalization of $125.26M compared with $111.21M for OnKure Therapeutics (OKUR).
Which stock has performed better over the past year, MGNX or OKUR?
MGNX returned +40.00% over the past 12 months, compared with +4.65% for OKUR (price return, excluding dividends). Past performance does not predict future results.
Are MacroGenics and OnKure Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.